Pharmaceutical applications of Ispaghula Husk: Mucilage

International Journal of Pharmaceutical Sciences Review and Research

Volumn 18, Issue 1, 2013, Pages 49-55

  Majmudar, H ^a   Mourya, V ^a   Devdhe, S ^b   Chandak, R ^b  

^a Department of Pharmaceutics   (India)

^b Yash institute of Pharmacy ^*

Author keywords

Chemical modification; Excipient; Mucilage; Natural carbohydrate; Plantago ovata

Indexed keywords

CALCIUM; CELLULOSE; ISPAGULA; POLYMER; SALICYLIC ACID; TETRACYCLINE;

CHEMICAL MODIFICATION; CHRONIC DIARRHEA; COLON CANCER; CONSTIPATION; CONTROLLED DRUG RELEASE; CROSS LINKING; DIABETES MELLITUS; DRUG ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DIFFUSION; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG INDICATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HYDROGEL; HYPERCHOLESTEROLEMIA; IRRITABLE COLON; MATERIAL COATING; MUCILAGE; PH; REVIEW; ULCERATIVE COLITIS;

EID: 84873856296     PISSN: 0976044X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. nd ed., CRC Press, Boca Raton, FL, USA (2006).
2. nd ed., CRC Press, Boca Raton, FL, USA (2006).
3. th edn, Elsevier, pp 210. 1997.
4. nd ed, Churchill livingstone, London, pp. 250. 1998.
5. http://ics.trieste.it/Medicinalplant/Medicinalplantdocument.aspx.
6. Kokate CK, Purohit AP, Gokhale SB, Text book of pharmacognosy, 31st ed., Nirali prakashan, Budhwar peth, Pune, pp. 149.
7. th ed., Elsevier, 1997, pp. 99.
8. th ed., The Pharmaceutical Press, London, 1993, pp. 900.
9. Kumar A, Kumar N, Vij JC, Sarin SK, Anand BS, Optimal dosage of ispaghula husk in patients with irritable bowel syndrome: correlation of symptom relief with whole gut transit time and stool weight. Gut 28, 1987, pp150-155.
10. Qvitzau S, Matzen P, Madsen P, Treatment of chronic diarrhoea: loperamide versus ispaghula husk and calcium. Scand. J. Gastroenterol. 23, 1988, pp. 1237-1240.
11. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvinej, Muller, Lissner SA, 1999. Functional bowel disorders and functional abdominal pain. Gut 45, pp. II43-II47.
12. Krammer H., Schieger F, Singer MV., Therapeutic option of chronic constipation. Internist (Berl.) 46, 2005, pp. 1331-1338.
13. Degan LP, Phillips SF, How well dose stool form reflects colonic transit? Gut 39, 1996, pp. 109-113.
14. Bouchoucha MG, Faye A, Savarieau B, Arsac M, Effect of an oral bulking agent and a rectal laxative administered alone or in combination for the treatment of constipation. Gastroenterol. Clin. Biol. 28, 2004, pp. 438-443.
15. Koch A, Voderholzer WA, Klauser AG, Muller-Lissner S, Symptoms in chronic constipation. Dis. Colon Return 40, 1997, pp. 902-906.
16. Clausen MR, Bonnen H, Mortensen PB, Colonic fermentation of dietary fiber to short chain fatty acids in patients with adenomotous polyps and colonic cancer. Gut 32, 1991, pp. 923-928.
17. Bijkerk CJ, Muris JW, Knottnerus, JA, Hoes AW, de Wit NJ, Systematic review: The roll of different types of fibre in the treatment of irritaee bowel syndrome. Aliment. Pharmacom. Ther. 19, 2004, pp. 245-251.
18. Brad JC, Calagiuri S, Crossman S, Allen A, Robertes DC, Truswell AS, Low-glycemic index foods improve long-term glycemic control in NIDDM. Diabetes Care 14, 1995, pp. 95-101.
19. Brennan CS, Dietary fiber, glycemic response, and diabetes. Mol. Nutr. Food Res. 49, 2005, pp. 560-570.
20. Anderson KM, Castelli WP, Levy D, Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 257, 1987, 2176-2128.
21. Anderson JW, Jones AE, Riddell-Mason S. Ten different dietary fibers have significantly different effects on serum and liver lipids of cholesterol-fed rats. J. Nutr. 124, 1994, 78-83.
22. Burton R, Manninen V, Influence of a psyllium-based fibre preparation on faecal and serum parameters. Acta Med. Scand. Suppl. 668, 1982, pp. 91-94.
23. Carr TP, Gallaher DD, Yang JK, Hessel CA, Inceased intestinal contents viscosity reduces cholesterol absorption efficiency in hamsters fed hydroxypropylmethyl cellulose. J. Nutr. 126, 1996, pp. 1463-1469.
24. Chavanpatil M, Jain P, Chaudhari S, Shea R, Vavia P, Development of sustained release gastoretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation. Int. Pharm. J., 304, 2005, pp. 178-184.
25. Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR, Novel sustained release, swelleble and bioadhesive gastroretentive drug delivery system for ofloxacin. Int. J. Pharm. 316, 2006, pp. 86-92.
26. Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR, Novel sustained release, swelleble and bioadhesive gastroretentive drug delivery system for ofloxacin. Int. J. Pharm. 316, 2006, 86-92.
27. Chiu HC, Hsiue GH, Lee YP, Huang LW, Synthesis and characterization of pH-sensitive dextran hydrogels as a potential colon-specific drug delivery system. J. Biomater. Sci. Polym. Ed. 10, 1999, 591-608.
28. Chourasia MK, Jain SK, Pharmaceutical approaches to colon targeted drug delivery system. J. Pharm. Sci. 6, 2003, 33-66.
29. Chourasia MK, Jain SK, Polysaccharides for colon targeted drug delivery. Drug Deliv., 11, 2004, 129-148.
30. Chiu HC, Hsiue HH, Lee YP, Huang LW, Synthesis and characterization of pH-sensitive dextran hydrogels as a potential colon-specific drug delivery system. J. Biomater. Sci. Polym. Ed. 10, 1999, pp. 591-608.
31. Christian J W, Renbarger JJ, Process for sterilizing psyllium seed husk using aqueous isopropanol (Phoenix, AZ); (Park Ridge, IL) G. D. Searle & Co. (Chicago, IL) 11/16/1976.
32. David R, Patel V K, Psyllium compositions Powell; Rowell Laboratories, Inc., 23-1982.
33. Rudin Richard E. S. C. Johnson & Son, Inc. (Racine, WI)., Easily dispersible dietary fiber product and method for producing the same., 5-1985.
34. Westerhof W, Landsmeer NL, Verschoor J, Teteringen NL, Use of polysaccharides in preparation for wound treatment Pharmalett International B. V. 20-1992.
35. Meer EH, Cresskill NJ, Mountain F (Ridgewood, NJ); Schultz; HV., Low calorie, high fiber laxative Meer Corporation 17-1991.
36. Diaz J A, Coconut Grove, FL, Naranjo E M, Miami FL, A Chemical composition for aiding the absorption, binding and elimination of undigested fat 10-1902.
37. Bell SJ, Shabert J, Brookline MA, Nutritional supplement for the management of stress Functional Foods, Inc. (Belmont, MA) 1-1904.
38. Adjei A L, Zhu NJ, Cutie AJ, Core formulation, Aeropharm Technology, Inc. (Edison, NJ) 8-1902.
39. Chourasia MK, Jain SK, Pharmaceutical approaches to colon targeted drug delivery system. J. Pharm. Sci. 6, 2003, pp. 33-66.
40. Shigehiro H, Kenji N, Min Z, Sun KK, Byung Geul Chung, Masatoshi Yoshikawa, and Takehiko Midorikawavave Chitosan staple fibers and their chemical modification with some aldehydes, Carbohydrate Polymers, Volume 38, Issue 4, April 1999, Pages 293-298.
41. Geresh S, Dawadi RP, Arad S, Chemical modifications of biopolymers: quatenization of the extracellular polysaccharide of the red microalga porphyridium sp., Carbohydrates polymers 63, 2000, pp. 75-80.
42. Kierulff Jesper Vallentin; U. S. Patent 6660503, Modification of polysaccharides by means of a phenol oxidizing enzyme.
43. Jianhong Yang and yumin Du, Chemical modification, characterization and bioactivity of chinese lacquer polysaccharides from lac tree Rhus vernicifera against leukopenia induced by cyclophosphamide, Carbohydrate polymers., 52 (4), 2003, pp. 405-410.
44. Jianhong Y, Yumin D, Chemical modification, characterization and bioactivity of chinese lacquer polysaccharides from lac tree Rhus vernicifera against leukopenia induced by cyclophosphamide, Carbohydrate polymers, 52(4), 2003, pp. 405-410.
45. Alonso ML, Prieto C, Calle AP, Sierra M, Influence of two dietary fibers in the oral bioavailability and other pharmacokinetic parameters of ethinyloestradiol. Contraception, 62, 2000, 253-257.